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Aspergilli are ubiquitous fungi with branched septate hyphae. Aspergillus produces a wide
variety of diseases determined by the inoculating dosage, the ability of the host to resist
infection at local and systemic levels, and the virulence of the organism. Invasive
pulmonary aspergillosis is more common in neutropenic, immunocompromised patients.
We describe the case of elderly male, recently diagnosed with myelodysplastic syndrome
presenting with complaints of repeated hemoptysis.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Aspergillus tracheobronchitis (AT) is an uncommon clinical
form of invasive pulmonary aspergillosis. Airway disease due
to Aspergillus ranges from relatively mild tracheobronchitis
with excess mucus production and inﬂammation to ulcera-
tive tracheobronchitis with ulcers and extensive pseudo-
membranous tracheobronchitis.Case report
A 74-year-old white male presented with productive cough,
associated with mild production of blood-streaked sputumElsevier Ltd. All rights reserved.
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. Amchentsev).for a period of 4 weeks. On further questioning he admitted
having shortness of breath on exertion, intermittent chest
pain and weakness.
His prior medical history was signiﬁcant for hypertension,
myocardial infarction, stroke, COPD, aortic valve replace-
ment, coronary artery bypass graft surgery, carotid endar-
terectomy and myelodysplastic syndrome. He had a remote
history of smoking. Recently he received two courses of
outpatient antibiotics with no signiﬁcant improvement in
clinical or functional status.
On physical examination he had normal vital signs,
purpura and ecchymoses on the arms, scattered rhonchi
bilaterally. Laboratory values were signiﬁcant for anemia,
thrombocytopenia and mild elevation of white blood cells.
Admission chest radiograph did not show any acute
inﬁltrates. While in the hospital, the patient was treated
for a respiratory infection, but he did not show signiﬁcant
improvement in symptoms. He continued to have productive
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phy (CT) of the chest showed patchy bilateral reticular
inﬁltrates with predominant peripheral distribution.
Flexible bronchoscopy showed a friable mucosa, white
plaques more pronounced in the left upper lobe (Figure 1).
These plaques were endoscopically biopsed. The biopsy
showed Aspergillus species with acute and chronic inﬂam-
mation of respiratory mucosa. The patient received Vor-
iconazole for a total of 8 weeks. After the treatment he
improved signiﬁcantly with resolution of symptoms. The
following surveillance bronchoscopy demonstrated a normal
airway (Figure 2).
Discussion
Invasive AT is an uncommon form of invasive aspergillosis,
where Aspergillus is limited predominantly to the tracheo-
bronchial tree, and is isolated in cultures with histopatho-Figure 2 Normal left upper lobe airways.
Figure 1 The left upper lobe friable mucosa, with presence of
white plaques.logical proof of tissue invasion, necrosis, ulceration or
pseudomembranes on bronchoscopy.1
The ﬁrst description of AT was done by Wheaton in 1890.
This entity is commonly associated with lung/heart trans-
plantation, AIDS, neutropenia, hematologic stem cell
transplant and hematologic malignancy, but it was also
reported in patients with burns, underlying lung disease,
SLE, malaria, viral infections, diabetes mellitus, renal and
hepatic failure. The reported incidence is around 7% in
patients with hematological malignancies, or severely
immunocompromised2; however, about 25% of patients with
AT are not apparently immunocompromised.3
The airway form of Aspergillosis is subdivided into
obstructive tracheobronchitis where thick mucous plugs
are present without inﬂammation, ulcerative tracheobron-
chitis with limited involvement of the tracheobronchial tree
and pseudomembranous necrotizing bronchial aspergillosis
with membranes containing Aspergillus and extensive
inﬂammation of the tracheobronchial tree.4
Host immunodeﬁciency (55% with neutropenia), T-cell
abnormalities and altered local defense mechanisms (en-
dotracheal tube, anastomosis in lung transplant) play a
signiﬁcant role in pathogenesis.3 AT is more common in less
severely immunocompromised patients, which may explain
the endobronchial localization. Young et al.5 observed that
patients with ATwere less neutropenic and had less exposure
to steroids and cytotoxic drugs than did the patients with
pulmonary parenchymal involvement.
Clinically 80% of patients with AT are symptomatic6
presenting with -speciﬁc complaints such as fever, dyspnea,
chest pain, cough, hemoptysis, but each symptom is only
seen in less than 50% of patients.2 On auscultation unilateral
wheezing can be heard when airways are obstructed by
inﬂammation, mucus plugs and fungal masses.7
Chest radiograph may not be helpful in the diagnosis of AT
and varies from normal to bilateral consolidation. CT
ﬁndings might show peribronchial consolidation/wall thick-
ening,8 with centrilobular nodules and branching linear
opacities known as ‘‘tree-in-bud’’ pattern.9 Bronchoscopy is
diagnostic, where yellow-white pseudomembranes are seen,
but endobronchial biopsy may be hazardous because of
possible transmural and vascular invasion.
Assays for the detection of the fungal cell wall constitu-
ents (galactomannan, (1,3)-b-D-glucan) have high sensitivity
in patients with hematological diseases, and low sensitivity
in patients with low risk for neutropenia.10,11 A leakage of
fungal cell wall components into the circulation will depend
on tissue invasion, causing limitation of these tests in
patients with AT. For instance, in one of the series of
patients who were diagnosed with AT, the highest galacto-
mannan serum ratio was below the cut-off level.12
AT is fatal in about 40% of cases despite appropriate
therapy with a noticeable increase of mortality rate in the
pseudomembranous necrotizing group (490%) and in me-
chanically ventilated patients.13
Management is similar to the other forms of invasive
aspergillosis. Treatment with azoles appears to be superior
to that of systemic amphotericine B.14 In cases of invasive
aspergillosis refractory to conventional treatment Capso-
fungin is indicated. If pseudomembranes cause an obstruc-
tion, the treatment of choice is mechanical ablation or
intubation with suctioning.15
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the incidence of Aspergillus infection has signiﬁcantly
increased. It warrants high clinical suspicion and awareness
among the pulmonologists, which can result in a prompt
diagnosis to facilitate early and appropriate treatment with
an attempt to prevent mortality or at least decrease
morbidity.
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